Simon Sturge
Président chez MOONLAKE IMMUNOTHERAPEUTICS
Fortune : 15 M $ au 30/06/2024
Profil
Dr. Simon J.
Sturge is an Independent Non-Executive Director at Galapagos NV, a Chairman at MoonLake Immunotherapeutics, an Executive Chairman at Mediar Therapeutics, Inc. and a Chairman at Moonlake Immunotherapeutics AG.
He is on the Board of Directors at Galapagos NV and Weizmann UK.
Dr. Sturge was previously employed as a Chief Executive Officer & Director by Kymab Ltd., an Independent Non-Executive Director by Feedback Plc, an Independent Non-Executive Director by Silence Therapeutics Plc, a Head-Biosimilars Unit by Merck KGaA, a Senior Vice President by Boehringer Ingelheim BV, a Chief Executive Officer by Dr. Reddy's Research & Development BV, a Manager-Business Development by Astra Pharmaceuticals Ltd., a Chairman-Supervisory Board by Cristal Delivery BV, a Chief Executive Officer & Director by Kymab Group Ltd., a Chief Executive Officer by Vernalis Plc, a Chief Executive Officer by Lonza Biologics Plc, a Chief Operating Officer by Merck Healthcare, and a Chief Executive Officer by RiboTargets Ltd.
He also served on the board at Celltech Group Plc.
He received his undergraduate degree from the University of Sussex.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 06/06/2024 | 342 980 ( 0,55% ) | 15 M $ | 30/06/2024 | |
GALAPAGOS NV
0,00% | 15/03/2024 | 180 ( 0,00% ) | 4 503 $ | 30/06/2024 |
Postes actifs de Simon Sturge
| Sociétés | Poste | Début |
|---|---|---|
| MOONLAKE IMMUNOTHERAPEUTICS | Président | 05/04/2022 |
| GALAPAGOS NV | Directeur/Membre du Conseil | 19/09/2023 |
Weizmann UK
 Weizmann UK Miscellaneous Commercial ServicesCommercial Services Weizmann UK is a non-profit company that operates scientific research institutes. The company is based in London, UK. The British company was founded in 1950. | Directeur/Membre du Conseil | - |
Mediar Therapeutics, Inc.
 Mediar Therapeutics, Inc. BiotechnologyHealth Technology Mediar Therapeutics, Inc. develops therapeutics to halt, reverse and fibrosis. The company was founded by Paul Yaworsky in 2018 and is headquartered in Cambridge, MA. | Président | 15/09/2021 |
Moonlake Immunotherapeutics AG
 Moonlake Immunotherapeutics AG Pharmaceuticals: MajorHealth Technology Part of MoonLake Immunotherapeutics, Moonlake Immunotherapeutics AG is a Swiss clinical-stage biopharmaceutical company. The company is based in Zug, Switzerland. The company was founded in 2021 by Arnout Ploos van Amstel, Jorge Santos da Silva, Kristian Reich. Moonlake Immunotherapeutics was acquired by Helix Acquisition Corp. on April 05, 2022 for $395.41 million. | Président | 10/08/2021 |
Anciens postes connus de Simon Sturge
| Sociétés | Poste | Fin |
|---|---|---|
Kymab Ltd.
 Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Directeur Général | 01/07/2021 |
| FEEDBACK PLC | Directeur/Membre du Conseil | 30/06/2021 |
| MERCK KGAA | Corporate Officer/Principal | 01/04/2019 |
| SILENCE THERAPEUTICS PLC | Président | 05/01/2015 |
| ░░░░░░░░░░ ░░░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Simon Sturge
| University of Sussex | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| MERCK KGAA | Health Technology |
| GALAPAGOS NV | Health Technology |
| SILENCE THERAPEUTICS PLC | Commercial Services |
| FEEDBACK PLC | Technology Services |
| MOONLAKE IMMUNOTHERAPEUTICS | Health Technology |
| Entreprise privées | 14 |
|---|---|
Ligand UK Ltd.
 Ligand UK Ltd. Pharmaceuticals: MajorHealth Technology Ligand UK Ltd. is a commercial stage pharmaceutical company. Its products include Tuzistra XR, targeting the U.S. prescription cough-cold market, Moxatag, a once-a-day formulation of the antibiotic and amoxicillin, and frovatriptan, used for the acute treatment of migraine. It also develops and commercializes multiple novel products focused on the U.S. prescription cough-cold market. The company was founded by Keith G. McCullagh and Andre L. Lamotte in 1988 and is headquartered in Winnersh, the United Kingdom. | Health Technology |
Celltech Group Plc
 Celltech Group Plc BiotechnologyHealth Technology Celltech Group Plc was one of the leading European biotechnology company which is engaged in discovery and development of innovative drugs. The company was located in Slough, United Kingdom. | Health Technology |
Lonza Biologics Plc
 Lonza Biologics Plc Miscellaneous Commercial ServicesCommercial Services Lonza Biologics Plc manufactures monoclonal antibodies, recombinant proteins and diagnostic monoclonal antibodies. The company was founded in 1897 and is headquartered in Slough, the United Kingdom. | Commercial Services |
| RiboTargets Ltd. | Health Technology |
Dr. Reddy's Research & Development BV
 Dr. Reddy's Research & Development BV Pharmaceuticals: MajorHealth Technology Dr. Reddy's Research & Development BV is engaged in the development and manufacture of injectable pharmaceutical products. It provides formulation, development, drug delivery, and clinical material manufacturing services to biotech and pharmaceutical companies worldwide. The company was founded by Joost J. M. Holthuis on July 20, 1995 and is headquartered in Leiden, Netherlands. | Health Technology |
Astra Pharmaceuticals Ltd.
 Astra Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Astra Pharmaceuticals Ltd. manufactures & wholesales pharmaceutical products. The company was established in 1908 and is headquartered in London, GB | Health Technology |
Boehringer Ingelheim BV
 Boehringer Ingelheim BV Drugstore ChainsRetail Trade An international, innovative, pharmaceutical, family business Boehringer Ingelheim BV is an international, innovative pharmaceutical company that focuses on the development and marketing of new drugs that help improve the health and welfare of humans and animals. The company was established in 1945 and is headquartered in Alkmaar, the Netherlands. | Retail Trade |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Weizmann UK
Weizmann UK Miscellaneous Commercial ServicesCommercial Services Weizmann UK is a non-profit company that operates scientific research institutes. The company is based in London, UK. The British company was founded in 1950. | Commercial Services |
Cristal Delivery BV
 Cristal Delivery BV Pharmaceuticals: MajorHealth Technology Cristal Delivery BV develops and manufactures nanomedicines for therapeutic drug optimization. It offers pipeline, oncology, and inflammation programs. The company was founded by Joost J. M. Holthuis and Cristianne Rijcken in April 2011 and is headquartered in Maastricht, the Netherlands. | Health Technology |
Mediar Therapeutics, Inc.
Mediar Therapeutics, Inc. BiotechnologyHealth Technology Mediar Therapeutics, Inc. develops therapeutics to halt, reverse and fibrosis. The company was founded by Paul Yaworsky in 2018 and is headquartered in Cambridge, MA. | Health Technology |
Kymab Group Ltd.
 Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million. | Health Technology |
| Merck Healthcare | |
Moonlake Immunotherapeutics AG
Moonlake Immunotherapeutics AG Pharmaceuticals: MajorHealth Technology Part of MoonLake Immunotherapeutics, Moonlake Immunotherapeutics AG is a Swiss clinical-stage biopharmaceutical company. The company is based in Zug, Switzerland. The company was founded in 2021 by Arnout Ploos van Amstel, Jorge Santos da Silva, Kristian Reich. Moonlake Immunotherapeutics was acquired by Helix Acquisition Corp. on April 05, 2022 for $395.41 million. | Health Technology |
